Proximal Ventures has closed its debut fund at $27.5 million. The San Francisco early-stage firm invests in Pre-Seed and Seed companies. It backs AI-native software and infrastructure across the life sciences value chain.
Fund backers
The fund closed above its initial $25 million target. Strategic partners include Domino Lane, SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and PagsGroup. Individual investors include Dimension co-founders Nan Li and Zavain Dar.
Founder approach
Sahir Raoof founded Proximal Ventures in 2026. He previously led techbio and pharmatech investing at SignalFire. The firm helps founders validate ideas, refine go-to-market strategy, and connect with pharma executives.
Advisory network
Founders gain access to an advisory network of regulatory and pharmaceutical leaders. Amy Abernethy formerly served as principal deputy commissioner at the U.S. Food and Drug Administration. Kim Branson serves as Chief AI Officer at GSK.
Proximal is now actively investing from Fund I. It seeks founders building the next generation of life sciences companies. Rohit Gupta, co-founder and CEO of Chronicle Bio, says the firm's network is shaping its approach.